Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

PolTREG begins CAR-Treg development for neuroinflammatory disease

Posted: 27 September 2024 | | No comments yet

After successful completion of the CAR-Treg preclinical study, the first in-human trial of the candidate to treat MS and ALS will commence.

Regulatory T cells

A study using CAR-Treg cells in a humanised mouse model of neuroinflammatory disease has been launched by PolTREG S.A, which will measure safety and efficacy of the CAR-Treg cell therapy and govern the pathway to clinical evaluation, with data expected by March 30, 2025.

Professor Piotr Trzonkowski, Chief Executive Officer of PolTREG, commented: “This first preclinical study of our CAR-Treg cell therapy programme to treat neurodegenerative disease is a significant milestone for PolTREG. This may be our first CAR-Treg cell therapy candidate, but we expect it to benefit tremendously from the experience our team built up during more than a decade in manufacturing, developing and treating patients with PTG-007.”

As a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs), PolTREG has its lead product PTG-007, an autologous Treg treatment for early-onset type-1 diabetes, ready for Phase II/III clinical testing. The CAR-Treg cells being used in the current preclinical study are derived from the company’s PTG-007 Treg cells which have 12 years of patient safety and efficacy data in type-1 diabetes from its leading technological and wholly owned GMP manufacturing facility in Poland.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

Professor Trzonkowski added: “This lengthy track record gives us several competitive advantages, as the next-generation engineered Tregs that we are adding to our pipeline come from the same platform and show a large degree of bioequivalence with PTG-007. Because of our proprietary technology and expertise, we expect to be able to develop our engineered therapies with greater ease than others in this field.”

Following the successful completion of the CAR-Treg preclinical testing, the company plan to begin the first-in-human trial of the engineered candidate to treat Multiple Sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

Furthermore, PolTREG is developing two additional modalities of engineered Treg cell therapies for autoimmune diseases: antigen-specific Tregs and T-cell receptor (TCR) Tregs. These are currently in early proof-of-concept stages.